share_log

Recursion Pharmaceuticals | 144: Notice of proposed sale of securities pursuant to Rule 144

SEC announcement ·  Mar 7 06:04
Summary by Futu AI
Recursion Pharmaceuticals, Inc. officer and director Christopher Gibson is set to sell 36,319 Class A shares on 03/06/2024, as per the latest filing. The shares, valued at approximately $430,671.77, were acquired through stock option exercises on various dates, with the most recent acquisition on 03/06/2024. Gibson's transactions over the past few months have involved the sale of 163,954 shares, generating gross proceeds of around $1,423,774.95. The upcoming sale is part of a plan adopted on 12/15/2022.
Recursion Pharmaceuticals, Inc. officer and director Christopher Gibson is set to sell 36,319 Class A shares on 03/06/2024, as per the latest filing. The shares, valued at approximately $430,671.77, were acquired through stock option exercises on various dates, with the most recent acquisition on 03/06/2024. Gibson's transactions over the past few months have involved the sale of 163,954 shares, generating gross proceeds of around $1,423,774.95. The upcoming sale is part of a plan adopted on 12/15/2022.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1

The information provided by Futu AI is automatically generated by third-party artificial intelligence (AI) software based on news content. It is only available to users located outside of China mainland.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.